NHS Improvement | July 2018 | The NHS saves £324 million in a year by switching to better value medicines
NHS Improvement have released figures that show how the NHS has made savings of £324 million using biosimilar medicines, a biological medicine highly similar to another biological medicine. These better value biosimilar and generic medicines, which are just as safe and effective as the more expensive original biological versions, an example being the Biosimilars of trastuzumab, breast cancer drug prescribed in place of the branded medicine Herceptin. They are also being used to treat conditions including rheumatoid arthritis, some forms of cancer and inflammatory bowel conditions.
Further details of savings can be found at NHS Improvement